Replies to post #122999 on Biotech Values

[genisi]

You're right on the terminology. What I meant is that by testing all those 3 combos VRUS makes the odds that its nuke(s) will be part of future all-oral DAA treatment very high.

[oc631]

Assuming the trials yield results, I imagine some formal licensing deals will be struck afterwards between the companies, if one of them doesn't outright acquire VRUS.

Whether licensing a deal or an outright takeover Pharmasset will play large pharma against one another and achieve incredible terms for shareholders.